Pretreatment with both AAV8.DN.ERK and AAV8.DN.p38 showed a trend towards even better survival (66 % mortality by 7 days) than AAV8.DN.ERK alone.
1
—
—
Pretreatment with both AAV8.DN.ERK and AAV8.DN.p38 showed a trend towards even better survival (66 % mortality by 7 days) than AAV8.DN.ERK alone.